{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001069530","name":"FILANA THERAPEUTICS, INC.","summary":"Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is a clinical-stage biotechnology company based in Austin, Texas, focused on developing medicines for CNS disorders. Its lead drug candidate, simufilam, is a proprietary small molecule oral treatment targeting filamin A protein, currently being studied for TSC-related epilepsy after discontinuing its Alzheimer's disease program in 2025. The company owns nine issued U.S. patents and holds an exclusive worldwide license from Yale University for simufilam's TSC-related applications.","people":[],"products":[{"name":"Simufilam","type":"platform","description":"Proprietary small molecule oral drug candidate targeting filamin A protein, studied for TSC-related epilepsy; formerly evaluated for Alzheimer's disease, now discontinued for that indication."}],"partnerships":[{"partner_name":"Yale University","partnership_type":"licensing","description":"Exclusive worldwide license granted February 26, 2025 for Yale's IP rights related to simufilam for TSC-related epilepsy and other indications, with milestone payments up to $4.5M and royalties.","start_date":null},{"partner_name":"TSC Alliance","partnership_type":"development","description":"Collaboration on preclinical study evaluating simufilam in Tsc1-CKO mouse model of TSC-related epilepsy, announced positive results in August 2025.","start_date":null},{"partner_name":"PsychoGenics, Inc.","partnership_type":"development","description":"TSC Preclinical Consortium's research partner that conducted preclinical study of simufilam in Tsc1-CKO mouse model.","start_date":null}],"affiliations":[],"origin":{"leaf":"8ebeb6ed19479c4f4d1e727876b5a3a3fa02e9add7d60854036454aff12a9214","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"5d1cd8514dba434515bfa04fdc030d784dbf45a5e729488208afe79fb746f50f","parent":"7adbdea932761367b4f0a6a04806423b03ceff2c6f1b68f2140455af3e81a730","source":"0001437749-26-007962","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":86,"hourly_limit":500,"remaining":414,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}